Gullik Håkan Wickholm
Director/Board Member at Beactica Therapeutics AB
Profile
Gullik Håkan Wickholm is currently a Director at Beactica Therapeutics AB and GHW Consulting AB.
Previously, he served as the Chief Executive Officer at Lytix Biopharma AS from 2014 to 2017.
He also worked as the Head-Regional Business Development at AstraZeneca.
AS and as a Director at Genovis AB.
Wickholm received his undergraduate degree from the University of Uppsala.
Gullik Håkan Wickholm active positions
Companies | Position | Start |
---|---|---|
Beactica Therapeutics AB
Beactica Therapeutics AB Medical DistributorsDistribution Services Beactica Therapeutics AB operates as a drug discovery company, utilizing its proprietary methodologies to evaluate the interactions of molecules in order to generate novel therapeutics. The firm's services include fragment-based lead generation, kinetic and mechanistic characterization of inhibitors, extended rate analysis, competition analysis, and antibody interaction analysis. The company was founded by Per K?llblad and Ulla Helena Danielson in 2006 and is headquartered in Uppsala, Sweden. | Director/Board Member | 31/12/2017 |
GHW Consulting AB | Director/Board Member | - |
Former positions of Gullik Håkan Wickholm
Companies | Position | End |
---|---|---|
AstraZeneca AS | Corporate Officer/Principal | - |
GENOVIS AB | Director/Board Member | - |
LYTIX BIOPHARMA | Chief Executive Officer | 06/09/2017 |
Training of Gullik Håkan Wickholm
University of Uppsala | Undergraduate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
GENOVIS AB | Health Technology |
LYTIX BIOPHARMA | Health Technology |
Private companies | 3 |
---|---|
AstraZeneca AS | |
Beactica Therapeutics AB
Beactica Therapeutics AB Medical DistributorsDistribution Services Beactica Therapeutics AB operates as a drug discovery company, utilizing its proprietary methodologies to evaluate the interactions of molecules in order to generate novel therapeutics. The firm's services include fragment-based lead generation, kinetic and mechanistic characterization of inhibitors, extended rate analysis, competition analysis, and antibody interaction analysis. The company was founded by Per K?llblad and Ulla Helena Danielson in 2006 and is headquartered in Uppsala, Sweden. | Distribution Services |
GHW Consulting AB |
- Stock Market
- Insiders
- Gullik Håkan Wickholm